As psilocybin-assisted healing becomes more accessible, one question comes up again and again: Can I take psilocybin if I’m on antidepressants like SSRIs? The short answer is: yes, you can. But it may affect how psilocybin works—and it may also raise deeper questions about what kind of healing you’re after.

In this post, we’ll explore how SSRIs and psilocybin interact, what the research says, and why some people are beginning to explore psychedelics as an alternative to long-term pharmaceutical treatment.

What if the next creative breakthrough doesn’t come from pushing harder—but from softening into presence, where inspiration can find you again?

In recent years, more artists, entrepreneurs, and everyday makers are turning to psilocybin, the active compound in “magic” mushrooms, not for escape—but for reconnection. Whether through microdosing or intentional journeys, this ancient medicine is helping people access something many of us have lost in the grind: our creative spark.

While the psychedelic experience may last only hours, its impact unfolds over days, weeks, even months—the real work begins after the journey ends. This phase, called integration, is where insights take root. It’s the space between revelation and reality—where visions become action, healing becomes habit, and altered states become lasting transformation.

For many navigating the grip of addiction, recovery can feel like an endless loop—momentum gained, then lost again. Attempts to quit are often met with shame, relapse, and the exhausting question of why nothing seems to stick. But emerging research suggests there may be a different way to interrupt the cycle, one rooted not in willpower or punishment, but in insight, neuroplasticity, and a deeper understanding of the pain beneath the pattern.

Let’s be real, psychedelics have a complicated reputation. For some, the word still conjures images of tie-dye and “bad trips.” For others, it's synonymous with personal healing, insight, and transformation. So let’s pause and ask: Where did the stigma come from? What does the science actually say now? And how do we create more informed, grounded conversations, especially as access continues to grow?

Psilocybin and other psychedelics are emerging as powerful tools in easing the emotional, spiritual, and existential distress that often accompanies terminal illness and cancer. With clinical research and compassionate care guiding the way, psychedelic-assisted support is helping many people find peace at the edge of life.

In the last few years, there’s been a quiet but powerful shift in how the medical world views psilocybin—the active compound found in certain psychedelic mushrooms. Once misunderstood or stigmatized, this naturally occurring substance is now being recognized for its potential to support healing, especially in people living with depression. In fact, the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy Designation to multiple psilocybin-based treatments. But what does that actually mean? And why does it matter?

This article explores a new Nature study on psilocybin's unique impact on brain connectivity. Unlike traditional antidepressants, psilocybin appears to increase global neural communication, offering insights into its long-term therapeutic potential. A must-read for anyone interested in the neuroscience behind psychedelic-assisted support.